Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparison of reduced intensity and nonmyeloablative conditioning for adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation in first or second remission.
Walter RB, Sandmaier BM, Othus M, Orvain C, Rodríguez-Arbolí E, Oshima MU, Schoch G, Davis C, Joachim Deeg H, Storb R. Walter RB, et al. Bone Marrow Transplant. 2023 Apr;58(4):377-385. doi: 10.1038/s41409-022-01909-x. Epub 2022 Dec 28. Bone Marrow Transplant. 2023. PMID: 36577856 Free PMC article.
Long-Term Impact of an Educational Antimicrobial Stewardship Program on Management of Patients with Hematological Diseases.
Guisado-Gil AB, Aguilar-Guisado M, Peñalva G, Lepe JA, Espigado I, Rodríguez-Arbolí E, González-Campos J, Rodríguez-Torres N, Montero-Cuadrado MI, Falantes-González JF, Reguera-Ortega JL, Gil-Navarro MV, Molina J, Pérez-Simón JA, Cisneros JM. Guisado-Gil AB, et al. Antibiotics (Basel). 2021 Jan 30;10(2):136. doi: 10.3390/antibiotics10020136. Antibiotics (Basel). 2021. PMID: 33573180 Free PMC article.
Augmented FLAMSA-Bu versus FluBu2 reduced-intensity conditioning in patients with active relapsed/refractory acute myeloid leukemia: an EBMT analysis.
Rodríguez-Arbolí E, Labopin M, Eder M, Brecht A, Blau IW, Huynh A, Forcade E, Tischer J, Bethge W, Bondarenko S, Verbeek M, Bulabois CE, Einsele H, Stölzel F, Savani B, Spyridonidis A, Bazarbachi A, Giebel S, Brissot E, Schmid C, Nagler A, Mohty M. Rodríguez-Arbolí E, et al. Bone Marrow Transplant. 2022 Jun;57(6):934-941. doi: 10.1038/s41409-022-01611-y. Epub 2022 Apr 7. Bone Marrow Transplant. 2022. PMID: 35393528
Phase 1/2 Trial of CLAG-M with Dose-Escalated Mitoxantrone in Combination with Fractionated-Dose Gemtuzumab Ozogamicin for Newly Diagnosed Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms.
Godwin CD, Rodríguez-Arbolí E, Othus M, Halpern AB, Appelbaum JS, Percival MM, Hendrie PC, Oehler VG, Keel SB, Abkowitz JL, Cooper JP, Cassaday RD, Estey EH, Walter RB. Godwin CD, et al. Cancers (Basel). 2022 Jun 14;14(12):2934. doi: 10.3390/cancers14122934. Cancers (Basel). 2022. PMID: 35740603 Free PMC article.
Contribution of measurable residual disease status to prediction accuracy of relapse and survival in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation.
Rodríguez-Arbolí E, Othus M, Orvain C, Zarling LC, Sandmaier BM, Milano F, Schoch G, Davis C, Deeg HJ, Appelbaum FR, Storb R, Walter RB. Rodríguez-Arbolí E, et al. Haematologica. 2023 Jan 1;108(1):273-277. doi: 10.3324/haematol.2022.281631. Haematologica. 2023. PMID: 36134457 Free PMC article. No abstract available.
26 results